癌症治療藥物引起的心臟毒性介紹及預防

Introduction and Prevention of Anti-Cancer Drugs-Induced Cardiotoxicity

饒坤銘(Kun-Ming Rau) ； 宋慧蒂(Hui-Ti Sung)

《腫瘤護理雜誌》 15卷1期 (2015/06) Pp. 1-7

https://doi.org/10.3966/168395442015061501001

摘要

進入二十一世紀後，癌症治療的進步是有目共睹，未來發展更是令人期待，包括化學治療，標靶治療，賀爾蒙治療及免疫治療，許多新藥正在進行臨床試驗及轉譯醫學研究。隨著研究的進步，癌症痊癒或有效控制的機會越來越高。如何在治療過程中兼顧成效與副作用，已是醫病需共同面對的課題，特別是長期治療累積可能產生的副作用，例如神經毒性，血液毒性以及心臟毒性等，其中心臟毒性發生比例雖然不高，但若警覺心不足，延誤治療，易有嚴重的併發症，甚至導致死亡。本文即回顧目前常用抗癌用藥心毒性的作用機轉，臨床症狀及處理方式，提供護理人員參考以提升臨床照護病患之安全。

關鍵字

癌症治療 ； 心臟毒性 ； 預防

並列摘要

Entering the 21st century, the progress on cancer treatment is obvious to people. The future development is much anticipating, including chemotherapy, target therapy, hormone therapy and immune therapy. Many clinical trials and translational medicine studies on new drugs are ongoing. With the progress on medicine, there is a better chance of cure on cancer or effective control. How to reach a compromise between treatment effectiveness and side effects during the treatment is a common issue for doctors and patients to deal with. Among the side effects particularly caused by the cumulative treatment, such as neural , blood and cardiac toxicities , the cardiac toxicity may cause severe complications and even death if neglectfully and delayedly treated, though it has a low occurrence rate. This article offers a review of mechanism of the cardiac toxicities of presently used chemotherapy drugs, clinical symptoms, and treatment protocol. It also provides nurses a reference to ensure the safety of patients during nursing.

並列關鍵字

cancer treatment ； cardiotoxicity ； prevention

參考文獻

Seidman A, Hudis C, Pierri MK, Shak S, Paton V, et al. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-1221.

Chen MH, Kerkela R, Force T. (2008). Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation 118: 84-95.

Swain SM, Whaley FS, Ewer MS. (2003). Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 97: 2869-2879.

Huelsenbeck SC, Schorr A, Roos WP, Huelsenbeck J, Henninger C, et al. (2012). Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons. J Biol Chem 287: 38590-38599.

Shelburne N, Adhikari B, Brell J, Davis M, Desvigne-Nickens P, et al. (2014) Cancer treatment-related cardiotoxicity: Current state of knowledge and future research priorities. J Natl Cancer Inst 106.